Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Feyereislova · SciRah

Researcher profile · Semantic Scholar

A. Feyereislova

Share profile

A. Feyereislova — researcher profile on SciRah

h-index: 20
Works: 37
Citations: 16K

Most-cited papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Y. Bang, E. Van Cutsem, A. Feyereislova, H. Chung +12 more
2010The Lancet6,861 citations Open access
Semantic Scholar
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
M. Fukuoka, S. Yano, G. Giaccone, T. Tamura +16 more
2003Journal of Clinical Oncology2,833 citations
Semantic Scholar
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
I. Smith, M. Procter, R. Gelber, S. Guillaume +20 more
2007The Lancet1,507 citations
Semantic Scholar
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
L. Gianni, W. Eiermann, V. Semiglazov, A. Manikhas +16 more
2010The Lancet1,229 citations
Semantic Scholar
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
B. Kaufman, J. Mackey, M. Clemens, P. Bapsy +8 more
2009Journal of Clinical Oncology853 citations Open access
Semantic Scholar
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
J. Baselga, D. Rischin, M. Ranson, H. Calvert +11 more
2002Journal of Clinical Oncology843 citations Open access
Semantic Scholar
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.
M. Ranson, L. Hammond, D. Ferry, M. Kris +9 more
2002Journal of Clinical Oncology786 citations Open access
Semantic Scholar
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.
J. Albanell, F. Rojo, S. Averbuch, A. Feyereislova +8 more
2002Journal of Clinical Oncology521 citations
Semantic Scholar
Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC).
E. Van Cutsem, Y.-K. Kang, H. Chung, Li Shen +6 more
2009Journal of Clinical Oncology229 citations
Semantic Scholar
Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC).
E. Van Cutsem, Y. Kang, H. Chung, A. Sawaki +5 more
2009Journal of Clinical Oncology94 citations
Semantic Scholar
Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non–small-cell lung cancer in the USA
Yulin Li, Anita Appius, T. Pattipaka, A. Feyereislova +2 more
2019PLoS ONE58 citations Open access
Semantic Scholar
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
P. LoRusso, R. Herbst, D. Rischin, M. Ranson +16 more
2003Clinical Cancer Research55 citations
Semantic Scholar
Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial.
L. Gianni, W. Eiermann, V. Semiglazov, G. Manikhas +5 more
200946 citations
Semantic Scholar
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
E. Van Cutsem, C. Verslype, P. Beale, Stephen J. Clarke +6 more
2008Annals of Oncology42 citations Open access
Semantic Scholar
Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis
L. Gianni, V. Semiglazov, G. Manikhas, W. Eiermann +6 more
200742 citations
Semantic Scholar
Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated.
B. Leyland-Jones, R. Colomer, M. Trudeau, A. Wardley +9 more
2010Journal of Clinical Oncology41 citations Open access
Semantic Scholar
2030 ORAL Efficacy of neoadjuvant trastuzumab in patients with inflammatory breast cancer: data from the NOAH (NeOAdjuvant Herceptin) Phase III trial
J. Baselga, V. Semiglazov, G. Manikhas, W. Eiermann +6 more
200726 citations
Semantic Scholar
Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors
A. Hanauske, J. Cassidy, J. Sastre, C. Bolling +6 more
2007Clinical Cancer Research23 citations Open access
Semantic Scholar
7BA Trastuzumab added to standard chemotherapy (CT) as first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC): efficacy and safety results from the Phase III ToGA trial
E. Van Cutsem, Y.-K. Kang, Li Shen, F. Lordick +6 more
200921 citations
Semantic Scholar
A phase 1b dose-escalation trial of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients
J. Delord, P. Beale, E. Van Cutsem, S. Clarke +6 more
200420 citations
Semantic Scholar
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
M. Fukuoka, S. Yano, G. Giaccone, T. Tamura +16 more
2022Journal of Clinical Oncology19 citations
Semantic Scholar
HER2 positivity in advanced gastric cancer is comparable to breast cancer
J. Leon-Chong, F. Lordick, Y.-K. Kang, S. Park +6 more
200716 citations
Semantic Scholar
A phase 1b dose-escalation trial of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients.
J. Delord, P. Beale, E. Van Cutsem, S. Clarke +6 more
2004Journal of Clinical Oncology8 citations
Semantic Scholar
Haemoperitoneum due to rupture of an ovarian endometrioid cyst as a first symptom of acute leukaemia.
P. Čepický, A. Feyereislova
1991Acta Clinica Belgica8 citations
Semantic Scholar
Hormone-receptor status and likelihood of predicting pathological complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC)
W. Eiermann, J. Baselga, V. Semiglazov, M. Byakhov +6 more
20086 citations
Semantic Scholar
Correction: Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA
Yulin Li, Anita Appius, T. Pattipaka, A. Feyereislova +2 more
2019PLoS ONE3 citations Open access
Semantic Scholar
Pooled cardiac safety analysis of patients with HER2-positive metastatic breast cancer receiving trastuzumab.
S. Muehlbauer, C. Révil, B. Leyland-Jones, R. Bell +4 more
20093 citations
Semantic Scholar
2120 POSTER Retreatment with trastuzumab after relapse following adjuvant trastuzumab treatment (the RHEA trial): preliminary efficacy data
R. Bell, F. Feng-yi, C. Barrios, Shu-Yan Yu +6 more
20073 citations
Semantic Scholar
Pharmacodynamic studies of the specific oral EGFR tyrosine kinase inhibitor (EGFR-TKI) zd1839 (‘Iressa’) in skin from cancer patients participating in phase I trials: histopathological and molecular consequences of receptor inhibition
J. Albanell, F. Rojo, Steven D. Averbuch, A. Feyereislova +6 more
20013 citations
Semantic Scholar
Circulating immune complexes in acute leukemia.
J. Čermák, A. Feyereislova, J. Hořejší
1989Neoplasma (Bratislava)3 citations
Semantic Scholar
Surgical aspect in NOAH Phase III trial (neoadjuvant trastuzumab in HER2-positive locally advanced breast cancer)
V. Semiqlazov, W. Eiermann, A. Manikhas, A. Bozok +6 more
20081 citations
Semantic Scholar
P3.01-044 Erlotinib vs Chemotherapy in EGFR Mut+ NSCLC: OS in Three Phase III Trials Adjusting for Post-Progression Treatment Crossover
Yong-Jian Wu, C. Zhou, M. Truman, A. Feyereislova +1 more
20170 citations Open access
Semantic Scholar
P3.01-040 Real-World Management of Patients with EGFR Mutation-Positive NSCLC in the US
Yulin Li, Anita Appius, T. Pattipaka, A. Feyereislova +2 more
20170 citations Open access
Semantic Scholar
Trastuzumab with chemotherapy in untreated HER2-positive advanced or metastatic gastric cancer
Y. Bang, Y.-K. Kang, H. Chung, Li Shen +6 more
20090 citations
Semantic Scholar
Pharmacodynamic S tudies o f t he E pidermal G rowth F actor Receptor I nhibitor Z D1839 i n S kin F rom C ancer P atients: Histopathologic a nd M olecular C onsequences o f Receptor I nhibition
J. Albanell, F. Rojo, S. Averbuch, A. Feyereislova +8 more
20020 citations
Semantic Scholar
Examination of serum ferritin and erythrocyte ferritin--its role in the blood transfusion service.
V. Šebestík, A. Feyereislova, J. Sejkorová, B. Friedmann +1 more
1990Folia haematologica0 citations
Semantic Scholar
[Profilometry in relation to lateral radiographic urethrocystography in women with urinary stress incontinence].
J. Feyereisl, J. Zikmund, J. Kobilková, T. Peterka +2 more
1986Ceskoslovenska gynekologie0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Baselga×10
Invite
J. Baselga — researcher profile on SciRah
E. Van Cutsem×8
Invite
E. Van Cutsem — researcher profile on SciRah
L. Gianni×8
Invite
L. Gianni — researcher profile on SciRah
D. Rischin×7
Invite
D. Rischin — researcher profile on SciRah

×7

Invite

S. Averbuch — researcher profile on SciRah

Invite

M. Lehle — researcher profile on SciRah

P. Valagussa×6

Invite

P. Valagussa — researcher profile on SciRah

V. Semiglazov×5

Invite

V. Semiglazov — researcher profile on SciRah

Invite

A. Lluch — researcher profile on SciRah

S. Tjulandin×5

Invite

S. Tjulandin — researcher profile on SciRah

Invite

A. Sawaki — researcher profile on SciRah

Invite

J. Baselga — researcher profile on SciRah